Literature DB >> 20560796

Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.

David Almond1, Tetsuya Kimura, XiangPeng Kong, James Swetnam, Susan Zolla-Pazner, Timothy Cardozo.   

Abstract

The diversity of HIV-1 is a confounding problem for vaccine design, as the human immune response appears to favor poor or strain-specific responses to any given HIV-1 virus strain. A significant portion of this diversity is manifested as sequence variability in the loops of HIV-1's surface envelope glycoprotein. Here we show that the most variable sequence positions in the third variable (V3) loop crown cluster to a small zone on the surface of one face of the V3 loop ss-hairpin conformation. These results provide a novel visualization of the gp120 V3 loop, specifically demonstrating a surprising preponderance of conserved three-dimensional structure in a highly sequence-variable region. From a structural point of view, there appears to be less diversity in this region of the HIV-1 "principle neutralizing domain" than previously appreciated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20560796      PMCID: PMC2932551          DOI: 10.1089/aid.2009.0254

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  32 in total

1.  An evaluation of beta-turn prediction methods.

Authors:  Harpreet Kaur; G P S Raghava
Journal:  Bioinformatics       Date:  2002-11       Impact factor: 6.937

2.  Coexpression of human immunodeficiency virus envelope proteins and tat from a single simian virus 40 late replacement vector.

Authors:  D Rekosh; A Nygren; P Flodby; M L Hammarskjöld; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

Authors:  M K Gorny; J Y Xu; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

5.  Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

Authors:  K A Page; N R Landau; D R Littman
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.

Authors:  G J Bridger; R T Skerlj; D Thornton; S Padmanabhan; S A Martellucci; G W Henson; M J Abrams; N Yamamoto; K De Vreese; R Pauwels
Journal:  J Med Chem       Date:  1995-01-20       Impact factor: 7.446

8.  Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

Authors:  E De Clercq; N Yamamoto; R Pauwels; J Balzarini; M Witvrouw; K De Vreese; Z Debyser; B Rosenwirth; P Peichl; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Sandra Cohen; Victoria R Polonis; William J Honnen; Samuel C Kayman; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

View more
  22 in total

1.  Assessment of immunologically relevant dynamic tertiary structural features of the HIV-1 V3 loop crown R2 sequence by ab initio folding.

Authors:  David Almond; Timothy Cardozo
Journal:  J Vis Exp       Date:  2010-09-15       Impact factor: 1.355

2.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Authors:  Catarina E Hioe; Terri Wrin; Michael S Seaman; Xuesong Yu; Blake Wood; Steve Self; Constance Williams; Miroslaw K Gorny; Susan Zolla-Pazner
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

3.  Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.

Authors:  Moumita Dutta; Jun Liu; Kenneth H Roux; Kenneth A Taylor
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

4.  Unbiased Identification of Immunogenic Staphylococcus aureus Leukotoxin B-Cell Epitopes.

Authors:  David N Hernandez; Kayan Tam; Bo Shopsin; Emily E Radke; Pegah Kolahi; Richard Copin; François-Xavier Stubbe; Timothy Cardozo; Victor J Torres; Gregg J Silverman
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 5.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

6.  Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Authors:  Susan Zolla-Pazner; X-P Kong; Xunqing Jiang; Timothy Cardozo; Arthur Nádas; Sandra Cohen; Maxim Totrov; Michael S Seaman; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

7.  Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus.

Authors:  Steven M Szczepanek; Roger W Barrette; Debra Rood; Diana Alejo; Lawrence K Silbart
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

8.  Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Authors:  Raiees Andrabi; Rajesh Kumar; Manju Bala; Ambili Nair; Ashutosh Biswas; Naveet Wig; Pratik Kumar; Rahul Pal; Subrata Sinha; Kalpana Luthra
Journal:  Virol J       Date:  2012-09-12       Impact factor: 4.099

9.  Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies.

Authors:  David Almond; Chavdar Krachmarov; James Swetnam; Susan Zolla-Pazner; Timothy Cardozo
Journal:  Adv Virol       Date:  2012-04-02

10.  Controlling the HIV/AIDS epidemic: current status and global challenges.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2012-08-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.